News

Midlife PSA measure predicted lethal prostate cancer


 

AT THE AUA ANNUAL MEETING

Dr. Preston reported having no disclosures. Dr. Eggener has been a consultant, adviser, lecturer, investigator, and/or proctor for Genomic Health, Intuitive Surgical Janssen Pharmaceuticals, and Myriad Genetics.

Pages

Recommended Reading

Panel recommends against low-dose CT for lung cancer in Medicare patients
MDedge Hematology and Oncology
CDC: Policy changes could prevent 100,000 deaths a year
MDedge Hematology and Oncology
Expanded cytoreduction criteria improved survival of carcinoid liver metastases
MDedge Hematology and Oncology
First SEER analysis including HER2 subtype is reported
MDedge Hematology and Oncology
Topical tazarotene did not improve response to imiquimod 5% in lentigo maligna
MDedge Hematology and Oncology
Polyp, adenoma detection rises with Endocuff device
MDedge Hematology and Oncology
Delaying ADT for PSA-only prostate cancer relapse appears safe
MDedge Hematology and Oncology
Obesity increased breast cancer mortality only in premenopausal women
MDedge Hematology and Oncology
Low-dose CT could up early lung cancer detection - at a price
MDedge Hematology and Oncology
Registry data: No increase in prostate cancer risk with long-term TRT
MDedge Hematology and Oncology